Background: Previous studies reported inconsistent effects of testosterone therapy on the lipid profile in men with hypogonadism.

Methods: Of 370 men with hypogonadism and T2DM, 190 received testosterone undecanoate 1000 mg/12 weeks (T-group) , 180 opted against treatment (CTRL) . Means and standard deviations of absolute measures over 13 years of treatment are reported.

Results: Mean baseline age: 62.0±5.2, mean (median) follow-up: 9.3±3.1 (10) years. Total cholesterol (TC) (mmol/L for all lipids) decreased from 8.3±1.1 to 5.1±0.3 in T-group and increased from 7.1±1.2 to 8.4±1.4 in CTRL (p<0.00for both) . HDL increased from 1.0±0.4 to 1.6±0.3 in T-group and decreased from 1.1±0.5 to 0.8±0.4 in CTRL (p<0.00for both) . The TC:HDL ratio decreased from 9.8±4.2 to 3.2±0.6 in T-group and increased from 8.0±3.9 to 13.8±6.8 in CTRL (p<0.00for both) .LDL decreased from 4.7±0.8 to 2.6±0.2 in T-group and increased from 4.1±1.4 to 5.2±1.6 in CTRL (p<0.00for both) . Triglycerides decreased from 3.5±0.6 to 2.2±0.1 in T-group and increased from 3.1±0.6 to 3.8±0.8 in CTRL (p<0.00for both) . Non-HDL decreased from 7.3±1.1 to 3.5±0.3 in T-group and increased from 6.0±1.4 to 7.7±1.5 in CTRL (p<0.00for both) . Remnant cholesterol decreased from 2.7±0.9 to 0.9±0.3 in T-group and increased from 2.0±1.0 to 2.5±0.7 in CTRL (p<0.00for both) . The triglyceride:HDL ratio decreased from 9.4±4.4 to 3.1±0.7 in T-group and increased from 8.0±4.0 to 14.1±6.9 in CTRL (p<0.00for both) .

Conclusions: Long-term treatment with TU in men with hypogonadism and T2DM improved the lipid profile, which worsened in controls.


F.Saad: Consultant; Bayer AG, Stock/Shareholder; AbbVie Inc., Bayer AG, GlaxoSmithKline plc. K.S.Haider: Other Relationship; Bayer AG. A.Haider: Other Relationship; Bayer AG.


Bayer AG

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at